Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported E.P.S. of $-1.05 for its first fiscal quarter (ending December 31) versus $-1.58 for the same period a year ago. Relative to the consensus estimate of $-1.35, this was a premium of $0.30. For the latest four quarters through December 31, E.P.S. were $-4.95 versus $-6.56 for the same period a year ago.
Recent Price Action
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) stock closed at $4.90 on 2/10/25 after being unchanged was unchanged. However, trading volume in this flat performance was exceptionally low at 49% of normal. The stock has declined -4.1% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Enanta Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects complementary signals from PTR’s two proprietary measures of a stock’s attractiveness. Enanta Pharmaceuticals has a slightly negative Appreciation Score of 36 and a very low Power Rating of 14, leading to the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment